Search peptides, terms, sources/
Regulatory source

Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks

About this source

Kind
Regulatory or official document
Primary or secondary
primary
Peer review
unknown
Retraction status
None known
Date checked
14 November 2026

Limitations

US FDA compounding categorisation. Not a UK regulatory position and not a marketing-authorisation decision. Page content current as of 22 April 2026. Only some peptides on the page are in Category 2 (for example ipamorelin and kisspeptin-10); others appear in a table of nominations that were withdrawn.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.